ABL Diagnostics has been selected by the Évry Commercial Court to acquire the assets and business operations of TEXCELL. The transaction, valued at an estimated €2.9 million, is designed to ensure business continuity and leverage synergies in virology, biosafety, and biological control. This strategic move allows ABL Diagnostics to expand its capabilities in molecular diagnostics and infectious diseases while maintaining operations at the Genopole site in Évry-Courcouronnes.

The acquisition scope includes the transfer of 29 employees, comprising 23 permanent staff and 6 apprentices or trainees. ABL Diagnostics will assume accrued employee rights amounting to €91,829.24, subject to final adjustment. The company plans to recruit approximately five additional employees to support the scientific activities derived from the acquisition.

Financial Terms of the Transaction

The overall economic value of the project is estimated at approximately €2.9 million. The financial structure includes several components allocated to assets, investments, and working capital.

The transaction is financed from the group’s available financial resources. The purchase price for assets comprises €165,000 for intangible assets and €60,000 for tangible assets. The acquisition of inventories is set at a lump-sum amount of €30,000 excluding VAT. Additionally, the company will assume lease financing agreements related to operational equipment, with future instalments amounting to €531,792.74, subject to final adjustment.

Strategic and Operational Synergies

TEXCELL, which originated from the scientific ecosystem of the Institut Pasteur, brings recognized expertise in viral safety, biosafety, genomic analysis, and immunological monitoring. According to publicly available information, TEXCELL France generated revenue of approximately €5.4 million in 2024, following €6.2 million in 2023 and €7.5 million in 2022. The acquisition complements ABL Diagnostics' existing platforms, including UltraGene, DeepChek®, and Nadis®.

This acquisition aligns with ABL Diagnostics' strategic initiatives with the Institut Pasteur, such as the HPV RNA-Seq genotyping project. The company intends to continue the scientific valorization of the acquired assets, including characterized virus banks and cell line collections. Dr. Chalom Sayada, Chief Executive Officer of ABL Diagnostics, stated that the transaction strengthens the company's position among leading international players in molecular biology and virology.

Future Outlook and Integration

ABL Diagnostics plans to invest in automation, infrastructure modernization, and team expansion to support laboratories and healthcare industry players worldwide. The company will provide further information regarding the integration of the acquired activities and their inclusion in its strategic roadmap for fiscal year 2026, subject to the completion of applicable legal and administrative formalities.

ABL Diagnostics announced that its reference shareholder, Advanced Biological Laboratories (ABL) S.A., has crossed below the threshold of 95% of the company's capital. Following various block trade transactions executed since 2025, ABL S.A. now holds 93.58% of the capital and 95.90% of the voting rights. This reduction marks a new milestone in the free float expansion strategy initiated by ABL since taking control of the company in October 2021 and reaffirmed during the 2022 merger. The strategy aims to broaden the shareholder base, improve stock liquidity, and enhance visibility among stakeholders.

The prospectus approved by the French Financial Markets Authority (AMF) on July 12, 2022, under visa number 22-296, outlined ABL's intention to expand the free float to potentially up to 30% of the share capital. Despite the reduction, ABL remains the majority shareholder and reaffirms its support for ABL Diagnostics' development strategy and international expansion. The company continues to focus on molecular diagnostics and infectious diseases, marketing products such as UltraGene and DeepChek® globally through its own sales team and exclusive distributors.

ABL Diagnostics serves academic clinical pathology laboratories, private reference laboratories, and researchers. The company has been marketing the products and services of its sister company CDL Pharma since the second half of 2025 through an intra-group strategy agreement. Its expanding portfolio includes HIV drug resistance testing, advanced detection solutions for SARS-CoV-2 and Tuberculosis, and microbiome analyses.

The company offers integrated solutions such as real-time syndromic PCR tests and Nadis®, a patient medical record used in over 200 hospitals in France. Headquartered in Woippy, ABL Diagnostics is a public limited company listed on compartment B of the regulated market of Euronext in Paris. Its molecular biology products generate recurring revenues and cover a large portfolio of applications in microbiology.

Key Details of the Filing